The GD1a glycan is a cellular receptor for adenoviruses causing epidemic keratoconjunctivitis
Author(s) -
Emma Nilsson,
Rickard Storm,
Johannes H. Bauer,
Silvia Johansson,
Aivar Lõokene,
Jonas Ångström,
Mattias Hedenström,
Thérèse Eriksson,
Lars Frängsmyr,
Simon Rinaldi,
Hugh J. Willison,
Fátima Pedrosa Domellöf,
Thilo Stehle,
Niklas Arnberg
Publication year - 2010
Publication title -
nature medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.536
H-Index - 547
eISSN - 1546-170X
pISSN - 1078-8956
DOI - 10.1038/nm.2267
Subject(s) - glycan , sialic acid , ganglioside , receptor , glycoprotein , antibody , biology , glycosylation , flow cytometry , virology , microbiology and biotechnology , chemistry , biochemistry , immunology
Adenovirus type 37 (Ad37) is a leading cause of epidemic keratoconjunctivitis (EKC), a severe and highly contagious ocular disease. Whereas most other adenoviruses infect cells by engaging CD46 or the coxsackie and adenovirus receptor (CAR), Ad37 binds previously unknown sialic acid-containing cell surface molecules. By glycan array screening, we show here that the receptor-recognizing knob domain of the Ad37 fiber protein specifically binds a branched hexasaccharide that is present in the GD1a ganglioside and that features two terminal sialic acids. Soluble GD1a glycan and GD1a-binding antibodies efficiently prevented Ad37 virions from binding and infecting corneal cells. Unexpectedly, the receptor is constituted by one or more glycoproteins containing the GD1a glycan motif rather than the ganglioside itself, as shown by binding, infection and flow cytometry experiments. Molecular modeling, nuclear magnetic resonance and X-ray crystallography reveal that the two terminal sialic acids dock into two of three previously established sialic acid-binding sites in the trimeric Ad37 knob. Surface plasmon resonance analysis shows that the knob-GD1a glycan interaction has high affinity. Our findings therefore form a basis for the design and development of sialic acid-containing antiviral drugs for topical treatment of EKC.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom